Glivec was also approved in 2003 for use in children with Ph+ chronic phase CML, which was recurrent after stem cell transplantation or resistant to INF-α therapy. The gene discussed is IFNA17; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.